If you haven’t been watching Generex Biotechnology Corporation (OTCMKTS:GNBT), you might want to start. The stock has been positively on fire in recent days in what looks for all the world to be genuine acceleration on strong accumulation. Shares are up over 100% on strengthening and strong volume in the past week, and there are several reasons why, one of which is likely the company’s recent announcement that it will dividend Generex shareholders with shares in its wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express), with the ultimate plan to spin out the company on a public exchange.
According to the release, “The dividend will be structured for Generex shareholders to receive 1 share of NuGenerex Immuno-Oncology for every 4 shares of Generex Biotechnology with the Record Date of Thursday, January 17, 2019, and a Payment Date of Monday, February 25, 2019.”
Generex Biotechnology Corporation (OTCMKTS:GNBT) bills itself as a company that, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.
It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices.
The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
According to company materials, “Generex Biotechnology Corp. (GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.”
Find out when $GNBT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, GNBT just announced that it will dividend Generex shareholders with shares in its wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express), with the ultimate plan to spin out the company on a public exchange.
According to the release, the stock dividend will result in the issuance of 1 share in NuGenerex Immuno-Oncology for every 4 shares of Generex Biotechnology common stock owned.
Recent action has seen 91% during the past month in terms of shareholder gains in the name. Furthermore, the name has seen a growing influx of trading interest, with the stock’s recent average trading volume running 66% above its longer-run average levels.
Now commanding a market cap of $153.14M, GNBT has a reserve ($2.4M) of cash on the books, which is balanced by about $42.9M in total current liabilities. One should also note that debt has been growing over recent quarters. GNBT is pulling in trailing 12-month revenues of $2.4M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 77408.9%. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $GNBT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $GNBT, either long or short, and we have not been compensated for this article.